Vertex Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones11-12

DJ Vertex Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. $(VRTX)$ slid 2.91% to $501.72 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.10% to 6,001.35 and the Dow Jones Industrial Average rising 0.69% to 44,293.13.

The stock's fall snapped a two-day winning streak.

Vertex Pharmaceuticals Inc. closed $18.16 short of its 52-week high ($519.88), which the company achieved on November 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Monday, as AbbVie Inc. $(ABBV)$ fell 12.57% to $174.43, Krystal Biotech Inc. (KRYS) fell 1.87% to $195.87, and Arcturus Therapeutics Holdings Inc. $(ARCT)$ rose 3.80% to $20.37.

Trading volume (1.3 M) eclipsed its 50-day average volume of 1.1 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 11, 2024.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

November 11, 2024 16:41 ET (21:41 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment